Scp8xx

Scp8xx is a preclinical-stage biologic candidate being developed by Silver Creek Pharmaceuticals using their proprietary "Smart-Biologics" platform. The program focuses on the creation of recombinant fusion proteins designed for cell-type specific targeting, which enables the precise delivery of potent therapeutic payloads—such as growth factors or cytokines—to specific cell populations. By localizing the activity of these biologics to the site of injury or disease, Scp8xx aims to maximize therapeutic efficacy in regenerative medicine and tissue repair while minimizing systemic off-target effects and toxicity. The specific molecular targets and primary disease indications for the Scp8xx series are currently undisclosed by the developer.